Massimiliano Tognolini
Parma, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors.
Journal: Biochemical pharmacology
Published: December 18, 2025
Target validation of natural compounds: Perillaldehyde case study.
Journal: International immunopharmacology
Published: November 25, 2025
Dual targeting of EphAs and KDR axis hampers VEGF-induced angiogenesis and glioma stem cell replication.
Journal: Biochemical pharmacology
Published: May 29, 2025
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present).
Journal: Expert opinion on therapeutic patents
Published: September 11, 2024
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line.
Journal: European journal of medicinal chemistry
Published: February 26, 2024
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction.
High-Density Lipoproteins at the Interface between the NLRP3 Inflammasome and Myocardial Infarction.
Journal: International journal of molecular sciences
Published: December 30, 2023
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity.
Journal: Journal of chemical information and modeling
Published: November 01, 2023
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 29, 2023
Drug discovery: In silico dry data can bypass biological wet data?
Journal: British journal of pharmacology
Published: July 10, 2023
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach.
Journal: Biochemical pharmacology
Published: December 01, 2022
A photosensitizing fusion protein with targeting capabilities.
Journal: Biomolecular concepts
Published: January 30, 2022
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 23, 2021
Last Updated: 09/26/2026